Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Deciphering the determinants of the intralesional immune reaction in cervical carcinogenesis may be conducive to improving the understanding of the disease and then improve outcomes.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Public gene‐expression data and full clinical annotation were searched in Gene Expression Omnibus in the joint analysis of the array‐based four eligible cohorts. The infiltrating estimation was quantified using microenvironment cell populations‐counter algorithm and absolute‐mode CIBERSORT and verified by flow cytometry analysis. An unsupervised classification on immune genes strongly associated with progression, designated by linear mixed‐effects regression. We determined immune response and signaling features of the different developmental stages and immune phenotypes by functional annotation and systematically correlated the expression of immune checkpoints with cell‐infiltrating characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>We identified the lesion‐intrinsic immunosuppression mechanism was triggered at precancerous stages, such as genome instability and mutation, aerobic glycolysis, activation of proto‐oncogene pathways and so forth. Predominant innate and adoptive cells were increasing from normalcy to cancer (B cell, total T cell, regulatory T cells [Tregs], monocytes, neutrophils, and M2‐like macrophages) together with the decrease of CD4<sup>+</sup> T cell and CD8<sup>+</sup> T cell through the development of cervical cancer. Immune escape initiated on the expression of immunosuppressive molecules from high‐grade squamous intraepithelial lesions (HSIL) and culminated in squamous cell carcinoma (SCC). Of note, the expression of immune checkpoints was escalated in the immune‐hot and immune‐warm phenotype largely encompassed by HSIL and SCC under the stress of both activated and suppressive immune responses. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Immune surveillance is unleashing from low‐grade squamous intraepithelial lesions onwards and immune‐suppression mechanisms are triggered in HSIL. Thorough knowledge of the immune changing pattern during cervical tumorigenesis contributes to finding the potential therapeutic targets to susceptive patients towards immune checkpoints inhibitors.</p></section>

Cervical Cancer: Emerging Immune Landscape and Treatment.

PD-1/PD-L1 Blockade in Cervical Cancer: Current Studies and Perspectives

The immune landscape during the tumorigenesis of cervical cancer

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature

Cervical Cancer Immunotherapy: Facts and Hopes

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Advances in immunotherapy for cervical cancer: recent developments and future directions

Cancer Immunotherapy: an Evolving Paradigm

Targeting HPV for the prevention, diagnosis, and treatment of Cervical Cancer

Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer

Advances in immunotherapy in cervical cancer

Tumor Immune Checkpoints and Their Associated Inhibitors

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus

Advances in Targeted Therapy for the Treatment of Cervical Cancer

Advances in cervical cancer: current insights and future directions

Highlighting the role of CD44 in cervical cancer progression: immunotherapy's potential in inhibiting metastasis and chemoresistance

Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge

Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions

Immune checkpoint inhibitors in cervical cancer: Current status and research progress